Federal grant · project grant (b)
Real-time Genetic Diagnosis at the Point of Care - Summary the Burden on Patients and Caregivers When Complex Diseases Arise Creates a Taxing Toll for Both Families and Healthcare Systems. Multiple Inpatient Hospitalizations and Various Testing Procedures Often Bring More Unknowns and Grief to an Already Difficult Situation. Hospital Visits Disrupt Patient Schedules, and Also Place Unnecessary Burdens on a Healthcare System Whose Purpose Is to Maximize the Health Outcomes of the Patients. These Complex Diseases Utilize Extra Visits and Unnecessary Testing. We Want to Develop a System That Would Identify Patients Who Could Benefit From Accessing Their Existing Genetic Information. Physicians May Struggle to Understand the Correct Time to Order Genetic Testing, and With the Rapid Pace of Change Within the Genetics Field, Many Physicians Are Not Utilizing the Genetic Testing That Is Available at an Appropriate Time. Genetic Testing Also Requires Hospital Resources From a Limited Pool of Workers, Thus Every Patient That Presents as a Complex Case May Not Be a Suitable Candidate for Genetic Testing. Identifying Which Patients Should Be Accessing Their Genetic Information Requires an Innovative Approach. at Geisinger, We Have a Cohort of 150,000 Patients Who Have Been Sequenced and We Currently Have Their Genetic Data. We Propose Starting With the Patients Clinical Presentations That Are Currently Charted Into an Electronic Health Record to Identify Phenotype Terms That Would Trigger Genetic Resources to Be Available. These Genetic Resources Would Include Workflows That Show Optimal Points of Impact for the Patients to Improve Healthcare Outcomes. to Realize This Vision, We Have Identified Three Areas That We Would Like to Address. Identification of Patients With a Candidate Condition in Real Time, Followed by a Concurrent Bioinformatic Analysis of the Genomic Sequence Data. Finally, We Want to Address Returning the Genetic Test Result to the Provider and Patient So That Both Parties Have the Appropriate Information to Guide Condition-specific Care. in Order to Address These Three Needs, We Have Developed Three Specific Aims With the Experts at Geisinger in Mind for Implementation. Aim 1. Development of a High Impact Phenotype Identification System (hipis). Aim 2. Develop Dynamic Virtual Genetic Panels (DVGP) for Real-time Genetic Diagnosis. Aim 3. Analysis of Clinical Workflows for Optimal Point of Care Integration of Real Time Genetic Diagnosis. Collaboration With Geisinger Experts as Well as Experts in Human Phenotyping (peter Robinson) Will Increase Understanding About Integrating Genetic Information Into Patient Care. This Transformation Will Allow the Work of Many Experts in Various Fields to Be Sitting at the Fingertips of Primary Care Physicians While Researching the Best Direction for Complex Diseases.
Committed
$4.6 Million
Paid out
$4.1M
90%
Committed, not yet paid
$470.9K
10%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.